Rigel surges as FDA waives pan­el; Trou­bled En­do­cyte looks for come­back fol­low­ing $12M li­cens­ing deal; Seat­tle Ge­net­ics scores a ‘break­through’

→ Shares of Rigel Ther­a­peu­tics $RIGL bound­ed up about 20% this morn­ing af­ter the biotech re­port­ed that the FDA has no plans to call an ex­pert pan­el to­geth­er to re­view fos­ta­ma­tinib in pa­tients with chron­ic or per­sis­tent im­mune throm­bo­cy­tope­nia. The FDA al­so has in­di­cat­ed that it ex­pects to hit its April 17, 2018, PDU­FA dead­line for a de­ci­sion. There are no guar­an­tees, of course, but that’s all gen­er­al­ly con­sid­ered pos­i­tive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER